Stockscreener 앱 받기
2.60
5.11%
-0.14
시장 영업 전:
2.60
전일 마감가:
$2.74
열려 있는:
$2.8
하루 거래량:
1.57M
Relative Volume:
0.65
시가총액:
$127.08M
수익:
-
순이익/손실:
$-67.68M
주가수익비율:
-1.5663
EPS:
-1.66
순현금흐름:
$-54.24M
1주 성능:
+18.72%
1개월 성능:
+9.24%
6개월 성능:
-63.33%
1년 성능:
-86.65%
1일 변동 폭
$2.485
$2.80
1주일 범위
$2.18
$2.85
52주 변동 폭
$1.76
$26.35
Cabaletta Bio Inc Stock (CABA) Company Profile
명칭
Cabaletta Bio Inc
전화
(267) 759-3100
주소
2929 ARCH STREET, PHILADELPHIA, PA
CABA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.60 | 127.08M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | 개시 | UBS | Buy |
| 2024-02-05 | 개시 | Jefferies | Buy |
| 2023-11-29 | 개시 | William Blair | Outperform |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 개시 | Stifel | Buy |
| 2023-09-05 | 개시 | Citigroup | Buy |
| 2023-07-18 | 개시 | Guggenheim | Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-01-08 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-13 | 개시 | H.C. Wainwright | Buy |
| 2019-11-19 | 개시 | Cowen | Outperform |
| 2019-11-19 | 개시 | Evercore ISI | Outperform |
| 2019-11-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Cabaletta Bio Inc 주식(CABA)의 최신 뉴스
Barclays PLC Buys 19,891 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio Discloses Unaudited Cash and Cash Equivalents of $164 Million as of December 31, 2024 - Defense World
HC Wainwright Reaffirms “Buy” Rating for Cabaletta Bio (NASDAQ:CABA) - Defense World
Cabaletta Bio (NASDAQ:CABA) Earns "Buy" Rating from HC Wainwright - MarketBeat
Brokerages Set Cabaletta Bio, Inc. (NASDAQ:CABA) PT at $24.38 - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Cabaletta Bio Advances Autoimmune Therapy, Sets Strategic Goals for 2025 - MSN
Cabaletta Bio stock maintain buy rating on trial progress - Investing.com India
Cabaletta Bio stock maintain buy rating on trial progress By Investing.com - Investing.com Australia
Cabaletta Bio's (CABA) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Cabaletta Bio Advances Clinical Trials with Lonza Partnership - TipRanks
Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025 - The Manila Times
A Look At The Behavior Of Hut 8 Corp (HUT) Stock - Stocks Register
Cabaletta Bio: Finding Optimism In Dire Straits (NASDAQ:CABA) - Seeking Alpha
Barclays PLC Has $288,000 Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Geode Capital Management LLC Raises Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Jane Street Group LLC Lowers Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Short Interest in Cabaletta Bio, Inc. (NASDAQ:CABA) Rises By 38.2% - MarketBeat
State Street Corp Sells 1,109,678 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Sold by State Street Corp - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Stock Rating Lowered by Evercore ISI - Defense World
Cabaletta Bio's SWOT analysis: autoimmune CAR-T stock faces challenges, opportunities By Investing.com - Investing.com South Africa
Cabaletta Bio's SWOT analysis: autoimmune CAR-T stock faces challenges, opportunities - Investing.com
Cabaletta Bio (NASDAQ:CABA) Downgraded by Evercore ISI to "Inline" - MarketBeat
Wells Fargo Downgrades Cabaletta Bio (CABA) - MSN
Charles Schwab Investment Management Inc. Raises Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday - Benzinga
Cabaletta Bio (NASDAQ:CABA) Downgraded to Equal Weight Rating by Wells Fargo & Company - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio's SWOT analysis: CAR-T pioneer's stock faces pivotal moment - Investing.com
Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth? - Simply Wall St
Point72 Asset Management L.P. Makes New $3.15 Million Investment in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Jennison Associates LLC Reduces Stake in Cabaletta Bio Inc - GuruFocus.com
PRUDENTIAL FINANCIAL INC's Strategic Acquisition of Cabaletta Bi - GuruFocus.com
Walleye Capital LLC Acquires 212,025 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio to Present Key Findings on CABA-201 at ACR Convergence 2024 - MSN
Weekly Analysts’ Ratings Updates for Cabaletta Bio (CABA) - Defense World
Unusually active option classes on open December 2nd - TipRanks
Cabaletta Bio (NASDAQ:CABA) Raised to Strong-Buy at TD Cowen - Defense World
Cabaletta Bio Sees Unusually High Options Volume (NASDAQ:CABA) - MarketBeat
US Stocks Likely To Open In The Green To End November On A High: Are Markets Set For A Santa Claus Rally In December? Analysts Decode - Benzinga
US Stocks Likely To Open In The Green To End November On A High: Are Markets Set For A Santa Claus Rally In December? Analysts Decode - Benzinga
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives $27.30 Consensus PT from Analysts - MarketBeat
Caballeta Bio Shares Surge The Most In 23 Months In A Single Day As It Unveils Plan To Meet FDA By 2025 For Systemic Sclerosis Drug Trial - Benzinga
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024 - MSN
Cabaletta Bio’s CAR-T CABA-201 Effects Clinical Responses in Autoimmune Diseases - CGTLive™
Cabaletta Bio to Participate in Upcoming Investor Conferences in December - The Manila Times
Cabaletta Bio Inc (CABA-Q) QuotePress Release - The Globe and Mail
Cabaletta Bio Inc (CABA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):